US SB1126 | 2019-2020 | 116th Congress

Status

Spectrum: Bipartisan Bill
Status: Introduced on April 10 2019 - 25% progression, died in committee
Action: 2019-04-10 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports.Additionally, the Centers for Medicare and Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Concentrating on High-value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2019

Sponsors


History

DateChamberAction
2019-04-10SenateRead twice and referred to the Committee on Finance.

Same As/Similar To

HB2283 (Related) 2019-04-11 - Referred to the Subcommittee on Health.

Subjects


US Congress State Sources


Bill Comments

feedback